CELLDEX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.67 USD | -0.21% |
|
-4.56% | -5.02% |
Presentation Operator MessageOperator (Operator)Welcome to the Celldex Therapeutics Mid-year 2...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Companyâs bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.
Calendar
2024-06-12
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
37.75
USD
Average target price
69
USD
Spread / Average Target
+82.78%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.02% | 2.49B | |
| +44.48% | 54.04B | |
| +43.57% | 41.96B | |
| -0.86% | 41.92B | |
| -7.59% | 28.35B | |
| +12.30% | 26.35B | |
| -21.83% | 19B | |
| +7.15% | 13B | |
| +29.40% | 12.28B | |
| +25.15% | 12.19B |
- Stock Market
- Equities
- CLDX Stock
- News Celldex Therapeutics, Inc.
- Transcript : Celldex Therapeutics, Inc., Q2 2020 Earnings Call, Aug 06, 2020